PQRS Success in 2015:

Similar documents
04/03/2015. Quality Matters: How to Succeed with PQRS in A Short History of PQRS. Participate Or Else..

2016 PQRS and VBM for Anesthesia and Pain Management

HIT Incentives: Issues of Concern to Hospitals in the CMS Proposed Meaningful Use Stage 2 Rule

United Medical ACO Participation Criteria

Proposed Meaningful Use Incentives, Criteria and Quality Measures Affecting Critical Access Hospitals

Olutoyin Abitoye, MD Attending, Department of Internal Medicine Virtua Medical Group New Jersey,USA

Fast Facts 2018 Clinical Integration Performance Measures

Q & A with Premier: Implications for ecqms Under the CMS Update

ASCs and Meaningful Use. Patrick Doyle, Vice President Sales Jessica McBrayer, RN, Business Analyst Ron Pelletier, Vice President Market Strategy

Stage 2 Meaningful Use: Menu Objectives and Clinical Quality Measures. James R. Christina, DPM Director Scientific Affairs APMA

An Overview of the. Measures. Reporting Initiative. bwinkle 11/12

Medicare & Medicaid. William Kassler, MD Chief Medical Officer Centers for Medicare & Medicaid Services Boston, MA

Minnesota Statewide Quality Reporting and Measurement System: Appendices to Minnesota Administrative Rules, Chapter 4654

National Hospital Inpatient Quality Reporting Measures Specifications Manual

Rural-Relevant Quality Measures for Critical Access Hospitals

7/7/17. Value and Quality in Health Care. Kevin Shah, MD MBA. Overview of Quality. Define. Measure. Improve

KANSAS SURGERY & RECOVERY CENTER

Minnesota Statewide Quality Reporting and Measurement System: Appendices to Minnesota Administrative Rules, Chapter 4654

Quality Health Indicators: Measure List. Clinical Quality: Monthly

THE BEST OF TIMES: PHARMACY IN AN ERA OF

Accountable Care and the Laboratory Value Proposition. Les Duncan Director of Operations Highmark Health - Home and Community Services

Meaningful Use Final Rule:

Benchmark Data Sources

Quality Health Indicators: Measure List. Clinical Quality: Monthly

How Does This Fit into the Provisions of the Affordable Care Act? The goals are aligned

Meaningful Use Measures: Quick Reference Guide Stage 2 (2014 and Beyond)

Quality Reporting: PQRS, CQM, GIQuIC. Erin Dettrey Product Manager, Analytics Sylvia Cohen gadvisor Team Lead Laurie Parker GIQuIC Executive Director

PATIENT SAFETY OVERVIEW

Hospital Inpatient Quality Reporting (IQR) Program Measures (Calendar Year 2012 Discharges - Revised)

2011 Measures 2013 Objectives Goal is to guide and support care processes and care coordination

HOW HOME HEALTH COMPARE ITEMS ARE CALCULATED

Minnesota Statewide Quality Reporting and Measurement System: Appendices to Minnesota Administrative Rules, Chapter 4654

PATIENT SAFETY KNOWLEDGEBASE. How to prepare for a Survey

Quality Care Amongst Clinical Commotion: Daily Challenges in the Care Environment

IMPROVING HCAHPS, PATIENT MORTALITY AND READMISSION: MAXIMIZING REIMBURSEMENTS IN THE AGE OF HEALTHCARE REFORM

Minnesota Statewide Quality Reporting and Measurement System: Appendices to Minnesota Administrative Rules, Chapter 4654

Hospital Compare Quality Measure Results for Oregon CAHs: 2015

ACO GPRO 2016 Ready to Report Basics GPRO ACO Random Sample Reporting January 17, 2017 to March 17, 2017

Quality Measurement and Reporting Kickoff

PATIENT SAFETY OVERVIEW

Calendar Year 2014 Medicare Physician Fee Schedule Final Rule

Value-based incentive payment percentage 3

Possible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436

NEW JERSEY HOSPITAL PERFORMANCE REPORT 2014 DATA PUBLISHED 2016 TECHNICAL REPORT: METHODOLOGY RECOMMENDED CARE (PROCESS OF CARE) MEASURES

WA Flex Program Medicare Beneficiary Quality Improvement Program

The HITECH EHR "Meaningful Use" Requirements for Hospitals and Eligible Professionals

MEDICARE BENEFICIARY QUALITY IMPROVEMENT PROJECT (MBQIP)

Minnesota Statewide Quality Reporting and Measurement System: APPENDICES TO MINNESOTA ADMINISTRATIVE RULES, CHAPTER 4654

Quality Measurement Approaches of State Medicaid Accountable Care Organization Programs

The Future of Physician Reimbursement

SANTA ROSA MEMORIAL HOSPITAL AND AFFILIATED ENTITIES ONGOING PROFESSIONAL PRACTICE EVALUATION POLICY (OPPE)

Presenter Disclosure Information

Beyond Meaningful Use: Driving Improved Quality. CHCANYS Webinar #1: December 14, 2016

Quality Measurement at the Interface of Health Care and Population Health

September 2, Dear Administrator Tavenner:

The Society of Thoracic Surgeons

Meaningful Use for 2014 Stag St e ag 1 Or Or Stag St e ag e 2 For Fo r 2014? Meaningful Meaningful Use: Stag St e ag e 1 1 Fo r Fo 2014

Goals & Challenges for Outpatient Quality Directors. Quality HealthCare Consulting, LLC CEO: Jennifer O'Donnell, MHA, PCMH-CCE

An Illustration in CLAS Bringing the Cultural and Linguistic Service Standards to Life

Medicare & Medicaid EHR Incentive Program Final Rule. Implementing the American Recovery & Reinvestment Act of 2009

Quality Payment Program MIPS. Advanced APMs. Quality Payment Program

EHR Incentives for Professionals and Hospitals. Paul Forlenza, VP Policy, VITL updated October 1, 2010 v.8.1

PRISM Collaborative: Transforming the Future of Pharmacy PeRformance Improvement for Safe Medication Management

CMS in the 21 st Century

Understanding PQRS and the Value-Based Modifier: CMS Plan to Achieve High Value Care through Transforming Payment Systems

HOSPITAL QUALITY MEASURES. Overview of QM s

Meaningful Use: a Primer

Meaningful Use Certification Details

Innovation. Successful Outpatient Management of Kidney Stone Disease. Provider HealthEast Care System

Hospital Outpatient Quality Measures. Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: January, 2018

Slide 1. Slide 2 Rural Princeton. Slide 3 Agenda Rural ACO RURAL ACOS CAN WORK AND LEAD THE WAY

Patient Experience Heart & Vascular Institute

Cleveland Clinic Implementing Value-Based Care

MACRA Fall into Place. By Stephanie Cecchini, CPC, CEMC, CHISP, AAPC Fellow, AAPC MACRA Prof

ACO SUCCESS STORY FROM A DIFFERENT PERSPECTIVE. By: Dr. Shelton Hager, Samantha Sizemore, and Dr. Alicia Wright

Clinical Operations. Kelvin A. Baggett, M.D., M.P.H., M.B.A. SVP, Clinical Operations & Chief Medical Officer December 10, 2012

Meaningful Use: Stage 1 and Beyond

VALUE. Critical Access Hospital QUALITY REPORTING GUIDE

10/10/2017. Mythbusters: Primary Care Edition (Expanding Opportunities) Amina Abubakar, PharmD, AAHIVP Olivia bentley, PharmD, CFts, AAHIVP

NEW JERSEY HOSPITAL PERFORMANCE REPORT 2012 DATA PUBLISHED 2015 TECHNICAL REPORT: METHODOLOGY RECOMMENDED CARE (PROCESS OF CARE) MEASURES

Quality Measurement, Population Health and Payment Reform

Quality and Improvement Activities Aaron Hubbard

2016 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES REGISTRY ONLY

Quality ID #46 (NQF 0097): Medication Reconciliation Post-Discharge National Quality Strategy Domain: Communication and Care Coordination

National Patient Safety Goals & Quality Measures CY 2017

CMS Transforming Clinical Practices Initiative and. The Southern New England Practice Transformation Network (SNE PTN)

Medicare Physician Payment Reform

Raising Awareness: Venous Thromboembolism Prevention and Reduction in the Orthopedic Patient Population

Primary Care Redesign Updates to DFM

QIN-QIO Sharing Call MIPS in the Real Word: How Your Peers Are Achieving Success. Wednesday, May 17, :00 4:00 PM ET

SHM has specific comments regarding the following measures in the Hospital Acquired Condition Payment Reduction Program:

Meaningful Use Stages 1 & 2

Using population health management tools to improve quality

CMS Value Based Purchasing: The Wave of the Future

MEANINGFUL USE STAGE 2

Quality: Finish Strong in Get Ready for October 28, 2016

2017 CMS Web Interface Quality Reporting. Questions & Answers January 2018

Goals and Objectives for Fiscal Year 2012

The History of Meaningful Use

Improving Quality of Care for Medicare Patients: Accountable Care Organizations

Transcription:

PQRS Success in 2015: The Effects of Applicability Validation (MAV) on s Selection for Hospitalists Why is Applicability Validation (MAV) important? CMS requires all eligible professionals (EPs) successfully report at least 9 measures covering at least 3 NQS quality domains during 2015 to avoid PQRS penalties (and, by association, potential P-VBP penalties as well). Additionally, if the clinician has at least one face-to-face patient encounter during the year, at least 1 of their reported measures must come from a short list of cross-cutting measure identified by CMS. Successfully reporting 9 measures, covering 3 domains, including 1 cross-cutting measure, satisfies the 2015 PQRS reporting requirements and eliminates the need for any further evaluation of the clinician s reporting. However, CMS recognizes that some physician specialties legitimately may not have 9 measures available to report, so they have devised a validation program that will allow clinicians to avoid the PQRS penalties while reporting fewer than 9 measures or fewer than 3 quality domains. How does MAV work? CMS connects certain groups of measures, considered to be clinically related, into clusters. If an EP reports fewer than 9 measures (or 3 domains), CMS will evaluate that EP s claims to see if there were any other measure the EP had at least 15 opportunities to report during the year, yet they did not report the measure. MAV clusters enter the equation at that point, because CMS will only look for other reportable measures that belong to the same MAV clusters as the measures already reported by that clinician. As a result, measures that are in very small MAV clusters (or are not in MAV clusters at all) are much less risky to report than measures that potentially pull many other measures into the MAV evaluation. Under MAV, if a physician falls short of the 9 measure/3 domain minimum, the more measures they did report, the more measures they have potentially pulled into their MAV evaluation that could be considered reportable by CMS. If an EP cannot reach 9 measures (and our experience with thousands of individual evaluations indicates that hospitalists almost universally cannot), identifying MAV cluster associations will be the single most important consideration in selecting measures to report for 2015.

Example 1 (Bad MAV): A clinician has decided to report measures A, B, and C (and only those measures) for 2015. Each of those measures belongs to a MAV cluster that results in several additional measures (D, E, F, G, H, I, J, and K) entering the clinician s MAV evaluation. If CMS finds (through analysis of claims paid to that clinician) that even one of those additional measures had been reportable at least 15 times during the program year, this clinician will fail the MAV process and incur the PQRS penalty. D E F Cluster 1 A B C G H I J K Cluster 2 Cluster 3 With this in mind, Ingenious Med s typical recommendations on what measures a group should and should not report in 2015 must take into account the additional considerations that MAV clusters impose. We have revised our advice from previous years while we used to recommend reporting more measures than you needed, we now recommend NOT attempting to reach 9 measures and, instead, report only as many measures as you can, while still limiting the liability MAV clusters might represent to your success. Example 2 (Good MAV): A clinician has decided to report measures X, Y, and Z (and only those measures) for 2015. None of those measures belong to MAV clusters, so no additional measures are evaluated for reportable events during MAV. This clinician avoids the PQRS penalty while reporting only 3 measures. X has no clustered measures X Y Z Y has no clustered measures Z has no clustered measures It is possible to (and even more probable that you will) avoid the PQRS penalties by reporting fewer than 9 measures, as long as you select the measures you do report carefully with respect to MAV clusters.

The flow chart below was taken directly from the 2015 CMS MAV documentation and demonstrates (through the path highlighted in green) how reporting fewer than 9 measure can enable the EP to pass MAV and avoid the PQRS penalty as long as that measures are not in MAV clusters (and contain at least one cross-cutting measure). MAV clusters are different for claims-based and registry-based reporting methods MAV clusters are defined very differently depending on the method of PQRS data submission a clinician uses for the 2015 reporting period. The MAV clusters defined for the claims-based reporting and registry-based reporting methods are completely different. As a result, practices should consider their reporting method before they begin reporting any PQRS data in 2015. If they are unsure which method they will use for data submission, their difficulty in predicting the effects of MAV will potentially be more complicated. There are some measures that are safe through both reporting methods, but most measures will introduce more MAV liability through one reporting method than the other.

What measures are recommended for inpatient physicians when considering the effects of MAV? For an inpatient practice, we recommend selecting the following measures, while taking into consideration aspects other than their MAV clusters, as detailed in our 2015 Inpatient Evaluations: 47 Advance Care Plan 130 Documentation of Current Medications 317 Preventive Care: BP Screening s #47 and #317 do not belong to MAV clusters in either the claims-based or the registry-based MAV, so they are excellent choices regardless of the intended submission method. #130 has no clustered measures when reported by registry, but shares a MAV cluster with measures #51 (COPD: Spirometry Evaluation) and #52 (COPD: Inhaled Bronchodilator Therapy) when reported by claims-based submission. However, measures #51 and #52 are only reportable on office H&Ps (99201-99205) and Office Follow-Ups (99212-99215), so most inpatient physicians would not have reportable events for those measures when they were examined through claims-based MAV. Additionally, each of these 3 measures are on the CMS list of cross-cutting measures, so reporting any one of them would satisfy the cross-cutting reporting requirement for 2015. There are measures listed below that may offer additional reporting opportunities for some groups, depending upon their clinical scope of practice. Again, the method of submission (claims or registry) will play a large part in selecting any additional measures that can safely be reported. Each measure selected should either belong to a cluster for which the physician can successfully report all other measures in the cluster, or belong to no cluster at all. Table 1: Inpatient measures with limited MAV liability when reported through claims 32 - Stroke: Discharged on Antithrombotic Therapy None 47* Advance Care Plan None 130* Documentation of Current Medications 3 (51, 52) 317* Preventive Care: BP Screening None Table 2: Inpatient measures with limited MAV liability when reported through registry 32 - Stroke: Discharged on Antithrombotic Therapy 21 (33, 187) 33 - Stroke: Anticoagulant Therapy Prescribed for Atrial 21 (32, 187) Fibrillation at Discharge 47* Advance Care Plan None 130* Documentation of Current Medications None 163 - Diabetes: Foot Exam None 187 - Stroke: Thrombolytic Therapy 21 (32, 33) 317* Preventive Care: BP Screening None

What about measure recommendations for specialists? Within the framework of PQRS measures, a surprising number of specialist actually have trigger patterns very similar to hospitalists. However, the extent to which their outpatient billing (if they do any) is performed outside of the Ingenious Med system can have a significant effect on their measure selection. If both their inpatient and outpatient charge capture is performed inside of IM (or if they perform no outpatient services), we can run a trigger analysis of their billing to recommend specific measures applicable to their practice. Any measures that demonstrate consistent trigger rates could be considered as options for reporting, taking any MAV clusters potentially involved into consideration during that process. Registry reporting may be an option for these users as well, which also factors into their measure selection (usually in a positive way). If a portion of their charge capture is performed inside of IM and another portion is performed outside of IM, Ingenious Med could only analyze the portion of their billing captured within our system. While that will give some indications of which measures the clinician could report, there may be other measures reportable by the clinicians that are triggered in the portion of their billing occurring outside of the IM environment, which introduces a degree of uncertainty into the analysis. Great care would be needed to select measures for these physicians, since having measures triggered outside of IM that belong to MAV clusters of measures triggered inside of IM (or vice versa) could be problematic. Reporting through IM s registry is not an option for these users, so they would reference the claims-based MAV clusters to evaluate their measures. IM can assist in that evaluation process, but our recommendations would be limited in scope, depending on the nature and extent of the charge capture going on outside of our system. Table 3: Specialist measures with limited MAV liability when reported through claims 46* - Medication Reconciliation None 110* - Preventive Care and Screening: Flu Vaccine None 111 - Preventive Care and Screening: Pneumonia None Vaccination for Patients 65+ 113 - Colorectal Cancer Screening None 134* - Preventive Care and Screening: Screening for None Clinical Depression and Follow-Up Plan 154 - Falls: Risk Assessment None 204 - IVD: Use of Aspirin or Another Antithrombotic None

Table 4: Specialist measures with limited MAV liability when reported through registry 21 - Perioperative Care: Selection of Prophylactic 22 (22, 23) Antibiotics 22 - Perioperative Care: Discontinuation of Prophylactic 22 (21, 23) Antibiotics 23 - Perioperative Care: Venous Thromboembolism (VTE) 22 (21, 22) Prophylaxis 46* - Medication Reconciliation None 54 - ED: 12-Lead ECG for Non-Traumatic Chest Pain None 110* - Preventive Care and Screening: Flu Vaccine None 111 - Preventive Care and Screening: Pneumonia None Vaccination for Patients 65+ 113 - Colorectal Cancer Screening None 128* - Preventive Care and Screening: BMI Screening and None Follow-Up 131* - Pain Assessment and Follow-Up None 134* - Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan 173 - Preventive Care and Screening: Unhealthy Alcohol None Use Screening 204 - IVD: Use of Aspirin or Another Antithrombotic None 226* - Preventive: Tobacco Screening and Cessation None Intervention Additional Resources: IM s 2015 Inpatient Evaluations MAV clusters for registry submission MAV clusters for claims-based submission CMS s MAV training course